The LYPLA2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt LYPLA2 gene function in human B lymphocytes. This stable loss-of-function model enables robust investigation of the lysophospholipase and depalmitoylase activities central to the protein palmitoylation cycle. The polyclonal nature ensures a diverse representation of editing events, supporting unbiased functional studies without clonal artifacts.
Raji cells, derived from a Burkitt??s lymphoma patient, are an EBV-transformed B lymphocyte line extensively utilized in immunology and oncology research. Their ability to produce antibodies and present antigens, combined with retention of B cell receptor signaling pathways, offers a physiologically relevant platform for studying palmitoylation dynamics in immune and cancer contexts. These cells grow in suspension and have been instrumental in deciphering mechanisms of B cell activation and transformation.
LYPLA2 functions as a depalmitoylase that cleaves palmitate from cysteine residues of substrate proteins, controlling their membrane localization and trafficking. Key targets include the oncogenic GTPases HRAS and NRAS, and the G-protein subunit GNAS. By reversing palmitoylation, LYPLA2 modulates downstream Ras/ERK and Wnt signaling cascades. The enzyme is a critical component of the palmitoylation?Cdepalmitoylation cycle, which governs the spatiotemporal activity of numerous palmitoylated signaling molecules.
In Raji B cells, LYPLA2 depletion likely disrupts palmitate turnover on key regulators of immune signaling, potentially altering B cell receptor-driven proliferation and survival. As a lymphoma-derived line, these knockout cells are particularly suited for investigating how aberrant depalmitoylation contributes to oncogenic Ras signaling and malignant transformation. They also provide a model for studying B cell-intrinsic roles of palmitoylation in antigen presentation and antibody production.
These knockout cells support diverse assays including western blotting, acyl-biotin exchange, immunofluorescence, co-immunoprecipitation, flow cytometry, and drug sensitivity testing. Applications range from tracking protein palmitoylation dynamics to evaluating targeted inhibitors in palmitoylation-disrupted lymphoma models. While optimized for B cell studies, the system provides insights applicable to neuronal and other cell types. This polyclonal knockout population provides a versatile tool for advancing understanding of protein palmitoylation in cancer and beyond. For further inquiries, please contact Ascent Research.
